PATENT
EP3256125
DOSING REGIMEN FOR PONESIMOD, A SELECTIVE S1P1 RECEPTOR AGONIST
EPO Register
Applicant(s)
Actelion Pharmaceuticals Ltd
Status
Opposition rejected
Status date
2026-11-06
Opposition filed
2022-10-28
Appeal filed
2024-12-12
Appeal decision
2026-10-15
Latest register event
2026-11-06
Family
54843844
Source: EPO Open Patent Services (epo-ops).
Court proceedings (1)
- 2026-10-12Laboratoires Juvise Pharmaceuticals v. Teva Pharmaceutical Industries Ltd., STADA Arzneimittel AG